Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma
- 15 December 2000
- Vol. 89 (12), 2521-2526
- https://doi.org/10.1002/1097-0142(20001215)89:12<2521::aid-cncr2>3.0.co;2-f
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1998
- Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.Journal of Clinical Oncology, 1996
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.Journal of Clinical Oncology, 1991
- Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.Journal of Clinical Oncology, 1990
- Combination Chemotherapy as an Adjuvant Treatment in Operable Breast CancerNew England Journal of Medicine, 1976